Reactions 1680, p38 - 2 Dec 2017 Acute hepatitis B infection: case report A 58-year-old woman developed acute hepatitis B infection following treatment with cyclophosphamide, doxorubicin, prednisone and vincristine [routes, dosages and outcome not stated]. The woman, who was diagnosed with diffuse large B-cell lymphoma, presented to the hospital with 1-week history of asthenia, nausea, vomiting and abnormal liver function. During admission, her serology was positive for hepatitis-B surface antigen (HBsAg) and hepatitis-B e antigen (HBeAg) and was negative for hepatitis-B surface antibody (HBsAb), antibodies of hepatitis-C virus, hepatitis-A virus, hepatitis-E virus and HIV. Her serum blood hepatitis-B virus (HBV) DNA concentration was 2.05 x 10 copies/mL. The limit of detection by PCR was 500 copies/mL. Her total bilirubin (TBIL), ALT and AST levels were 38.4 µmol/L (normal: 0 19.1 µmol/L), 581 U/L – – (normal: 0 45 U/L), 324 U/L (normal: 0 37 U/L), respectively. She was diagnosed with an acute hepatitis-B based on the typical clinical results and her past history. The woman was treated with entecavir and radix glycyrrhizae agent. After 4 weeks’ therapy, the HBV-DNA concentration fell below detectable levels and her serum AST and AST levels returned to almost normal limits. Six weeks after starting the entecavir therapy, she presented E-antigen serological conversion. Her HBsAg disappeared after 9 weeks. After 12 weeks of the treatment, her HBsAb was tested positive. Subsequently, the entecavir therapy was discontinued. Subsequent investigations revealed that, 8 years ago, she had been vaccinated against hepatitis-B and had consistent records of HBsAb positive. About 8 weeks before the hospitalisation, she had latest test for HBsAb when she was preparing to receive tumour chemotherapy. The precise titer was 78.6 IU/L. Nearly 4 months earlier, she was diagnosed with diffuse large B-cell lymphoma and received the CHOP regimen which consisted of cyclophosphamide, vincristine, doxorubicin and prednisone. Substantial side effects of chemotherapy included hair loss, anorexia, and decreased platelets and leukocyte counts. About 4 weeks after the chemotherapy completion, the symptomatic hepatitis-B virus infection appeared. Based on her medical history and the incubation period of the hepatitis-B virus infection, it was assumed that, she possibly acquired the infection during the chemotherapy or in a very short time after it. About 5 weeks before she developed obvious acute hepatitis related symptoms, she was transfused with 1 platelet unit (blood transfusion) for improvement of thrombocytopenia. Subsequent donor investigations revealed that, the donor was asymptomatic acute HBV infected person and woman’s CHOP chemotherapy weakened her immune system and enhanced the body sensitivities leading to development of acute hepatitis B infection. Author comment: "The case reported here demonstrated that tumor chemotherapy with the CHOP regimen might have weakened the immune system of this lymphoma patient and enhanced the body sensitivities to hepatitis B virus, then led to the infection, though she had a reliable record of HBsAb positive." "Substantial side effects included hair loss, anorexia, and decreased platelets and leukocytes." Kang FB, et al. Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report. Medicine 96: e8518, No. 44, Nov 2017. Available from: URL: http://doi.org/10.1097/MD.0000000000008518 - China 803285333 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera